Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mylan Enters Market in Japan by Acquiring Merck's Generic Drug Business
October 15, 2007
- Public Opinions Invited on Documents Required for Applications for Generics
October 15, 2007
- Mitsubishi Tanabe Pharma Corp. Aims at Becoming Global Drug Discovery Company
October 15, 2007
- Kaken Completes PIIb Trial for KCB-1D as Drug to Regenerate Periodontal Tissue
October 15, 2007
- Taisho Licenses Psychiatric Drug Candidates to BrainCells
October 15, 2007
- Silodosin Was Found to Be Superior to Tamsulosin: Kissei
October 15, 2007
- EPS Ties Up with Medidata Solutions Regarding EDC Software
October 15, 2007
- First Gene Therapeutic to Regenerate Blood Vessels Expected in 2008
October 15, 2007
- VITAL-NET, KSK Enter into Comprehensive Business Alliance
October 15, 2007
- Physician-Initiated Trials Led by JMACCT Generating Results
October 15, 2007
- Council Recommends Improvements of Drug Trade Practices
October 15, 2007
- Guideline Issued on Multinational Cooperative Clinical Studies
October 15, 2007
- JMA Does Not Support NHI Pricing System Proposed by Industry
October 8, 2007
- JT, Torii License New Drug for Hyperphosphatemia from Keryx
October 8, 2007
- GSK Applies for Cervical Cancer Vaccine
October 8, 2007
- Wyeth Applies for the Pneumococcus Vaccine Prevenar
October 8, 2007
- Yasuo Fukuda Elected Prime Minister
October 8, 2007
- BUSINESS NEWS IN BRIEF
October 8, 2007
- Japan Should Switch to Mixed Vaccines: Dr Kamiya
October 8, 2007
- SSRIs Effective against Post-stroke Depression: Pfizer Seminar
October 8, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…